FDA: Focus on Hardest to Treat in Cohort Cancer Trials By Sam | August 10, 2018 The FDA says sponsors considering adaptive studies for early phase cancer treatments should focus on patients with no other options. Source: Drug Industry Daily Posted in Drug Industry Daily